Trials / Conditions / Locally Advanced Pancreatic Ductal Adenocarcinoma

Locally Advanced Pancreatic Ductal Adenocarcinoma

17 registered clinical trials studyying Locally Advanced Pancreatic Ductal Adenocarcinoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT07089940	OHSU Knight Cancer Institute	EARLY_Phase 1
Recruiting	A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combinati NCT07157033	Xerient Pharma	Phase 1 / Phase 2
Withdrawn	STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256	City of Hope Medical Center	Phase 1
Recruiting	Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620	British Columbia Cancer Agency	N/A
Recruiting	PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626	Samsung Medical Center	Phase 2
Withdrawn	FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma NCT06206876	Roswell Park Cancer Institute	Phase 1
Recruiting	A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatmen NCT07101679	West China Hospital	Phase 2
Recruiting	Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer NCT06600906	University of California, San Francisco	—
Withdrawn	Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-adva NCT06398587	OHSU Knight Cancer Institute	Phase 2
Recruiting	AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC NCT06472037	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Active Not Recruiting	New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancrea NCT04481204	M.D. Anderson Cancer Center	Phase 2
Recruiting	Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline NCT05688215	Jonsson Comprehensive Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284	Flemming Forsberg	Phase 1 / Phase 2
Completed	Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma NCT04292743	Georgetown University	Phase 1
Suspended	NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreati NCT04484909	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable NCT04106856	University of Utah	Phase 1
Recruiting	Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690	OHSU Knight Cancer Institute	EARLY_Phase 1